SHANGHAI – At this year's China Healthcare Investment Conference, the most insistent voices were not Chinese but American. Three speakers – a former U.S. federal judge, a leading biotech entrepreneur and a China pharma executive – each made their case for China's biopharma industry to have more influence, not just in China but globally.